Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jullien

Showing results (1141-1150 of 1,158) with videos related to

Pageof 116
Sort By:
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
Joint Bone Spine|June 28, 2011
TNF alpha antagonist therapy and safety monitoringThao Pham, Hervé Bachelez, Jean-Marie Berthelot, et al.
Critical Care (London, England)|March 15, 2024
Impact of COVID-19 on posttraumatic stress disorder in ICU survivors: a prospective observational comparative cohort studyPierre Kalfon, Wissam El-Hage, Marie-Agnès Geantot, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2014
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patientsMarie Jachiet, Béatrice Flageul, Alban Deroux, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
Orphanet Journal of Rare Diseases|March 28, 2013
Experimental designs for small randomised clinical trials: an algorithm for choiceCatherine Cornu, Behrouz Kassai, Roland Fisch, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
The Journal of Allergy and Clinical Immunology|October 19, 2020
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based studySatveer K Mahil, Nick Dand, Kayleigh J Mason, et al.
Pageof 116

Showing results (1141-1150 of 1,158) with videos related to

Sort By:
Pageof 116
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
Joint Bone Spine|June 28, 2011
TNF alpha antagonist therapy and safety monitoringThao Pham, Hervé Bachelez, Jean-Marie Berthelot, et al.
Critical Care (London, England)|March 15, 2024
Impact of COVID-19 on posttraumatic stress disorder in ICU survivors: a prospective observational comparative cohort studyPierre Kalfon, Wissam El-Hage, Marie-Agnès Geantot, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2014
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patientsMarie Jachiet, Béatrice Flageul, Alban Deroux, et al.
The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
Orphanet Journal of Rare Diseases|March 28, 2013
Experimental designs for small randomised clinical trials: an algorithm for choiceCatherine Cornu, Behrouz Kassai, Roland Fisch, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
The Journal of Allergy and Clinical Immunology|October 19, 2020
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based studySatveer K Mahil, Nick Dand, Kayleigh J Mason, et al.
Pageof 116